Advances in soft mist inhalers

References

• Liang W, Pan HW, Vllasaliu D, et al. Pulmonary delivery of biological drugs. Pharmaceutics. 2020;12(11):1025. doi: 10.3390/pharmaceutics12111025
   PubMed Web of Science ®Google Scholar
• Dalby RN, Eicher J, Zierenberg B. Development of respimat(®) soft mist™ inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl). 2011;4:145–155.
   PubMedGoogle Scholar
• Worth Longest P, Hindle M. Evaluation of the respimat soft mist inhaler using a concurrent CFD and in vitro approach. J Aerosol Med Pulm Drug Deliv. 2009;22(2):99–112. doi: 10.1089/jamp.2008.0708
   PubMed Web of Science ®Google Scholar
• Sorino C, Negri S, Spanevello A, et al. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler. Eur J Intern Med. 2020;75:15–18. doi: 10.1016/j.ejim.2020.02.023
   PubMed Web of Science ®Google Scholar
• Newman SP. AEROSOLS, in encyclopedia of respiratory medicine. G.J. Laurent and S.D. Shapiro, Editors. Academic Press;Oxford: 2006p. 58–64. doi: 10.1016/B0-12-370879-6/00019-3
   Google Scholar
• Alatrash A, Mehri R, Ogrodnik N, et al. Experimental study of spiriva respimat soft mist inhaler spray characterization: size distributions and velocity. J Aerosol Med Pulm Drug Deliv. 2019;32(5):293–302. doi: 10.1089/jamp.2018.1501
   PubMed Web of Science ®Google Scholar
• Stefan Leiner DC, Eicher J, de Kruijf W, et al. Soft Mist Inhalers. Pharma Inhalation Aerosol Technol. 2019;3:493–507.
   Google Scholar
• Anderson P. Use of respimat soft mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2006;1(3):251–259. doi: 10.2147/copd.2006.1.3.251
   PubMedGoogle Scholar
• Dekhuijzen PN, Lavorini F, Usmani OS. Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®). Patient Prefer Adherence. 2016;10:1561–1572. doi: 10.2147/PPA.S82857
   PubMed Web of Science ®Google Scholar
• P R. Delivering biologics with soft mist inhalers – a market poised to expand. Qatar Med J. 2022;(4):45–48. 10.5339/qmj.2022.45
   PubMedGoogle Scholar
• de Kruijf W, Müllinger B. Do soft mist inhalers hold the key to faster inhalation drug development? ONdrugDelivery. 2022;2022(131):62–65.
   Google Scholar
• Dalby R, Spallek M, Voshaar T. A review of the development of respimat soft mist inhaler. Int J Pharm. 2004;283(1–2):1–9. doi: 10.1016/j.ijpharm.2004.06.018
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Dalby RN. Clinical implications of the tiotropium/olodaterol inhaler for patients with chronic obstructive pulmonary disease. Postgrad Med. 2018;130(6):515–522. doi: 10.1080/00325481.2018.1481713
   PubMed Web of Science ®Google Scholar
• Delvadia RR, Longest PW, Hindle M, et al. In vitro tests for aerosol deposition. III: effect of inhaler insertion angle on aerosol deposition. J Aerosol Med Pulm Drug Deliv. 2013;26(3):145–156. doi: 10.1089/jamp.2012.0989
   PubMed Web of Science ®Google Scholar
• Lavorini F, Janson C, Braido F, et al. What to consider before prescribing inhaled medications: a pragmatic approach for evaluating the current inhaler landscape. Ther Adv Respir Dis. 2019;13:1753466619884532. doi: 10.1177/1753466619884532
   Web of Science ®Google Scholar
• Ke WR, Wang W-J, Lin T-H, et al. In Vitro evaluation of aerosol performance and delivery efficiency during mechanical ventilation between soft mist inhaler and pressurized metered-dose inhaler. Respir Care. 2020;65(7):1001–1010. doi: 10.4187/respcare.06993
   PubMed Web of Science ®Google Scholar
• Hochrainer D, Hölz H, Kreher C, et al. Comparison of the aerosol velocity and spray duration of Respimat soft mist inhaler and pressurized metered dose inhalers. J Aerosol Med. 2005;18(3):273–282. doi: 10.1089/jam.2005.18.273
   PubMedGoogle Scholar
• Zierenberg B. Optimizing the in vitro Performance of Respimat. J Aerosol Med. 1999;12(s1):S-19-S–24. doi: 10.1089/jam.1999.12.Suppl_1.S-19
   Google Scholar
• Oliveira R, Ferreira A, Teixeira S, et al. PMDI spray plume analysis: aCFD study. 2013;3.
   Google Scholar
• McCabe JC, Koppenhagen F, Blair J, et al. ProAir(®) HFA delivers warmer, lower-impact, longer-duration plumes containing higher fine particle dose than Ventolin(®) HFA. J Aerosol Med Pulm Drug Deliv. 2012;25(2):104–109. doi: 10.1089/jamp.2011.0891
   PubMed Web of Science ®Google Scholar
• Finlay WH, Darquenne C. Particle Size Distributions. J Aerosol Med Pulm Drug Deliv. 2020;33(4):178–180. doi: 10.1089/jamp.2020.29028.whf
   PubMed Web of Science ®Google Scholar
• Wittner M, Karbstein H, Gaukel V. Pneumatic atomization: beam-steering correction in laser diffraction measurements of spray droplet size distributions. Appl Sci. 2018;8(10):1738. doi: 10.3390/app8101738
   Google Scholar
• Ong HX, Traini D, Cipolla D, et al. Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. Pharm Res. 2012;29(12):3335–3346. doi: 10.1007/s11095-012-0827-0
   PubMed Web of Science ®Google Scholar
• Lelong N, Junqua-Moullet A, Diot P, et al. Comparison of laser diffraction measurements by mastersizer x and spraytec to characterize droplet size distribution of medical liquid aerosols. J Aerosol Med Pulm Drug Deliv. 2013;27(2):94–102. doi: 10.1089/jamp.2012.1030
   PubMed Web of Science ®Google Scholar
• Dahl R, Kaplan A. A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter? BMC Pulm Med. 2016;16(1):135. doi: 10.1186/s12890-016-0291-4
   PubMed Web of Science ®Google Scholar
• Abdou EM, Kandil SM, Morsi A, et al. In-vitro and in-vivo respiratory deposition of a developed metered dose inhaler formulation of an anti-migraine drug. Drug Deliv. 2019;26(1):689–699. doi: 10.1080/10717544.2019.1618419
   PubMed Web of Science ®Google Scholar
• Bernhard Muellinger NAB, Bartholomew J, de Kruijf W. Aerosol performance of the single-use Pulmospray™ soft mist inhaler for inhalation of high amounts of liquid formulations. J Aerosol Med Pulm Drug Deliv. 2021;34(5):A-1-A–22.
   Web of Science ®Google Scholar
• Muellinger B, Buchmann N, Bockenstedt D, et al. Effect of Inspiratory flow rate on particle size distribution and in silico deposition within the respiratory tract using a Soft Mist Inhaler (SMI). Respir Drug Delivery. 2022; 343–348.
   Google Scholar
• Newman SP, Brown J, Steed KP, et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of respimat with conventional metered-dose inhalers with and without spacer devices. Chest. 1998;113(4):957–963. doi: 10.1378/chest.113.4.957
   PubMed Web of Science ®Google Scholar
• Erdelyi T, Lazar Z, Farkas Á, et al. Modeling of pulmonary deposition of agents of open and fixed dose triple combination therapies through two different low-resistance inhalers in COPD: a pilot study. Front Med. 2023;10:10. doi: 10.3389/fmed.2023.1065072
   Web of Science ®Google Scholar
• Iwanaga T, Tohda Y, Nakamura S, et al. The Respimat(®) Soft mist inhaler: implications of drug delivery characteristics for patients. Clin Drug Investig. 2019;39(11):1021–1030. doi: 10.1007/s40261-019-00835-z
   PubMed Web of Science ®Google Scholar
• Ciciliani A-M, Denny M, Langguth P, et al. Lung deposition using the respimat® soft mist™ inhaler mono and fixed-dose combination therapies: an in vitro/in silico analysis. COPD. 2021;18(1):91–100. doi: 10.1080/15412555.2020.1853091
   PubMedGoogle Scholar
• Ammari WG, Khalil Mohammad M, Tayyem RF. Evaluation of patients’ real-world post-dispensing use and storage environments of tiotropium bromide Respimat® soft mist inhaler on its in vitro dose delivery and lung deposition. Pulm Pharmacol Ther. 2019;58:101829. doi: 10.1016/j.pupt.2019.101829
   PubMed Web of Science ®Google Scholar
• Wong CYJ, Cuendet M, Spaleniak W, et al. Validation of a cell integrated next-generation impactor to assess in vitro drug transport of physiologically relevant aerosolised particles. Int J Pharmaceut. 2022;624:122024. doi: 10.1016/j.ijpharm.2022.122024
   PubMed Web of Science ®Google Scholar
• Marasini N, Sheikh Z, Wong CYJ, et al. Development of excipients free inhalable co-spray-dried tobramycin and diclofenac formulations for cystic fibrosis using two and three fluid nozzles. Int J Pharm. 2022;624:121989. doi: 10.1016/j.ijpharm.2022.121989
   PubMedGoogle Scholar
• Mehri R, Slew KL, Alatrash A, et al. Aerosol deposition measurements with ODAPT mask adapter. 2018.
   Google Scholar
• Brand P, Hederer B, Austen G, et al. Higher lung deposition with respimat soft mist inhaler than HFA-MDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3(4):763–770. doi: 10.2147/COPD.S3930
   PubMedGoogle Scholar
• Wei X, Hindle M, Kaviratna A, et al. In Vitro tests for aerosol deposition. vi: realistic testing with different mouth-throat models and in vitro-in vivo correlations for a dry powder inhaler, metered dose inhaler, and soft mist inhaler. J Aerosol Med Pulm Drug Deliv. 2018;31(6):358–371. doi: 10.1089/jamp.2018.1454
   PubMed Web of Science ®Google Scholar
• Sadeghi T, Pakzad L, Fatehi P. Evaluation of soft mist inhaler aerosol velocity, size, and deposition inside the mouth—a computational fluid dynamics study. J Biomech Eng. 2023;145(6):1–45. doi: 10.1115/1.4056967.
   Web of Science ®Google Scholar
• Zierenberg B. Optimizing the in vitro performance of Respimat. J Aerosol Med. 1999;12 Suppl 1(s1):S19–24. doi: 10.1089/jam.1999.12.Suppl_1.S-19
   PubMedGoogle Scholar
• Martin AR, Finlay WH. Nebulizers for drug delivery to the lungs. expert opinion on drug delivery. Expert Opin Drug Delivery. 2015;12(6):889–900. doi: 10.1517/17425247.2015.995087
   PubMed Web of Science ®Google Scholar
• Finlay W. The mechanics of inhaled pharmaceutical aerosols. 2001.
   Google Scholar
• de Boer A, Wissink J, Hagedoorn P, et al. In Vitro performance testing of the novel medspray® wet aerosol inhaler based on the principle of Rayleigh break-up. Pharm Res. 2008;25(5):1186–1192. doi: 10.1007/s11095-007-9503-1
   PubMed Web of Science ®Google Scholar
• Müllinger WDKAB Soft Mist Inhalers (SMIs): Addressing Unmet Needs In Inhaled Product Development. 2022; Available from: https://www.recipharm.com/system/files?file=RDD-2022-workshop-SMI-1.pdf.
   Google Scholar
• Wilhelmus Petrus Johannes De Kruijf CJMVR, Nijdam W, Joseph Van Egmond H. Atomizer device. U. Patent, editors. United States: Justia Patent. May 12 2022.
   Google Scholar
• Henri Van Egmond WPJDK, Nijdam W, Mathijn Wissink J. Cornelis Johannes Maria Van Rijn, AEROSOL or SPRAY DEVICE, SPRAY NOZZLE UNIT and METHOD of MANUFACTURING the SAME. Medspray B.V. (Enschede). Geneva, Switzerland: World Intellectual Property Organization; 2020 Apr 28.
   Google Scholar
• Wietze Nijdam (Enschede) HJVEE, Van Rijn (Amsterdam) CJM. Fluidic sprayer. 2021 May 25. MEDSPRAY B.V. (Enschede). US Patent and Trademark Office, Virginia, United States.
   Google Scholar
• Rayleigh L. On the instability of jets. Proceedings of The London Mathematical Society, London; 1878; 4–13. 1
   Google Scholar
• Klein DM, Poortinga A, Verhoeven FM, et al. Degradation of lipid based drug delivery formulations during nebulization. Chem Phys. 2021;547:111192.
   Web of Science ®Google Scholar
• Cortez-Jugo C, Masoumi S, Chan PPY, et al. Nebulization of siRNA for inhalation therapy based on a microfluidic surface acoustic wave platform. Ultrason Sonochem. 2022;88:106088. doi: 10.1016/j.ultsonch.2022.106088
   PubMed Web of Science ®Google Scholar
• Rajapaksa AE, Do LAH, Suryawijaya Ong D, et al. Pulmonary deposition of radionucleotide-labeled palivizumab: proof-of-concept study. Front Pharmacol. 2020;11:11. doi: 10.3389/fphar.2020.01291
   PubMed Web of Science ®Google Scholar
• Marqus S, Lee L, Istivan T, et al. High frequency acoustic nebulization for pulmonary delivery of antibiotic alternatives against Staphylococcus aureus. Eur J Pharm Biopharm. 2020;151:181–188. doi: 10.1016/j.ejpb.2020.04.003
   PubMed Web of Science ®Google Scholar
• Perriello EA, Sobieraj DM. The respimat soft mist inhaler, a novel inhaled drug delivery device. Conn Med. 2016;80(6):359–364.
   PubMedGoogle Scholar
• Hodder R, et al. Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat® soft mist™ inhaler in COPD. Int J Chron Obstruct Pulmon Dis. 2011;6:245–251. doi: 10.2147/COPD.S16094
   PubMed Web of Science ®Google Scholar
• Tashkin DP. The safety of anticholinergic bronchodilators for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015;14(11):1759–1772. doi: 10.1517/14740338.2015.1093621
   PubMed Web of Science ®Google Scholar
• Ari A, Fink JB. Recent advances in aerosol devices for the delivery of inhaled medications. Expert Opin Drug Delivery. 2020;17(2):133–144. doi: 10.1080/17425247.2020.1712356
   PubMed Web of Science ®Google Scholar
• SOFTHALE [Internet]. Belgium: SOFTHALE; [cited 2023 Jun 28]. Available from: https://www.softhale.com/[Internet].
   Google Scholar
• Cipolla D, Bruinenberg P, Eliahu P, et al. Development of an inhaled AERx essence nicotine product for smoking cessation. In: Dalby RN, Byron PR, Peart J, Suman JD, and Farr SJ, editors. Respir Drug Delivery. River Grove, IL: Davis Healthcare Int’l Publishing LLC. 2008;169–175.
   PubMedGoogle Scholar
• Erelel M, Kaskal M, Akbal-Dagistan O, et al. Early Effects of low molecular weight heparin therapy with soft-mist inhaler for COVID-19-induced hypoxemia: a phase iib trial. Pharmaceutics. 2021;13(11):1768. doi: 10.3390/pharmaceutics13111768
   PubMed Web of Science ®Google Scholar
• T N. A Phase I study investigating the delivery of tobramycin using TobrAir device compared with TOBI/PARI LC PLUS and TOBI Podhaler using pharmacokinectic and pharmacoscintigraphic methods. Respir. Drug Deliv. 2016;3:485–488.
   Google Scholar
• van Geffen GJ, Markerink H, van Barneveld M, et al. Comparative in-vitro study of the trachospray, a new device for topical anaesthesia of the upper airway. Med Devices (Auckl). 2021;14:9–14. doi: 10.2147/MDER.S292529
   PubMedGoogle Scholar
• van Geffen GJ, Markerink H, van Barneveld M, et al. Clinical evaluation of the Trachospray device for upper airway anaesthesia. Anaesthesia. 2021;76(4):569–570. doi: 10.1111/anae.15348
   PubMed Web of Science ®Google Scholar
• Medspray [Internet]. Netherlands: Medspray; [cited 2023 Jun 28]. Available from: https://medspray.com/our-products/.
   Google Scholar
• Aerami therapeutcis [Internet]. Durham: Aerami; [cited 2023 Jun 28]. Available from: https://www.aerami.com/pipeline.
   Google Scholar
• Anzueto A, Miravitlles M. Tiotropium in chronic obstructive pulmonary disease - a review of clinical development. Respir Res. 2020;21(1):199. doi: 10.1186/s12931-020-01407-y
   PubMed Web of Science ®Google Scholar
• Laube BL, Dolovich MB. 66 - Aerosols and Aerosol Drug Delivery Systems. In: Adkinson NF, editor. Middleton’s Allergy. 8th ed. London: W.B. Saunders. 2014; 1066–1082. doi: 10.1016/B978-0-323-08593-9.00067-X
   Google Scholar
• Dhand R, Eicher J, Hänsel M, et al. Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler. Int J Chron Obstruct Pulmon Dis. 2019;14:509–523. doi: 10.2147/COPD.S190639
   PubMed Web of Science ®Google Scholar
• Schuster J, Rubsamen R, Lloyd P, et al. The AERX aerosol delivery system. Pharm Res. 1997;14(3):354–357. doi: 10.1023/A:1012058323754
   PubMed Web of Science ®Google Scholar
• Deshpande DS, Blanchard JD, Schuster J, et al. Gamma scintigraphic evaluation of a miniaturized AERx pulmonary delivery system for aerosol delivery to anesthetized animals using a positive pressure ventilation system. J Aerosol Med. 2005;18(1):34–44. doi: 10.1089/jam.2005.18.34
   PubMedGoogle Scholar
• Chan H-K, Chiou H, Kwok P. The 15th international society of aerosols in medicine congress. Expert Opin Drug Delivery. 2006;3(1):163–167. doi: 10.1517/17425247.3.1.163
   PubMedGoogle Scholar
• Thipphawong JB, Babul N, Morishige R, et al. Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery. Anesthesiology. 2003;99(3):693–700. discussion 6A. doi: 10.1097/00000542-200309000-00026
   PubMed Web of Science ®Google Scholar
• Otulana B, Okikawa J, Linn L, et al. Safety and pharmacokinetics of inhaled morphine delivered using the AERx system in patients with moderate-to-severe asthma. Int J Clin Pharmacol Ther. 2004;42(8):456–462. doi: 10.5414/CPP42456
   PubMed Web of Science ®Google Scholar
• Davison S, Thipphawong J, Blanchard J, et al. Pharmacokinetics and acute safety of inhaled testosterone in postmenopausal women. J Clin Pharmacol. 2005;45(2):177–184. doi: 10.1177/0091270004269840
   PubMed Web of Science ®Google Scholar
• Okumu FW, Lee R-Y, Blanchard JD, et al. Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. Pharm Res. 2002;19(7):1009–1012. doi: 10.1023/A:1016559707084
   PubMed Web of Science ®Google Scholar
• Sangwan S, Agosti JM, Bauer LA, et al. Aerosolized protein delivery in asthma: gamma camera analysis of regional deposition and perfusion. J Aerosol Med: The Official J Intern Socr Aerosols In Med. 2001;14(2):185–195. doi: 10.1089/08942680152484117
   PubMedGoogle Scholar
• Geller D, Thipphawong J, Otulana B, et al. Bolus inhalation of rhDnase with the AERx system in subjects with cystic fibrosis. J Aerosol Med. 2003;16(2):175–182. doi: 10.1089/089426803321919933
   PubMedGoogle Scholar
• Cipolla D, Gonda I. Inhaled nicotine replacement therapy. Asian J Pharm Sci. 2015;10(6):472–480. doi: 10.1016/j.ajps.2015.07.004
   Web of Science ®Google Scholar
• Bruinenberg DCCGOMR. Deep lung pulmonary delivery of treprostinil. United States: Aradigm Corp; 2012.
   Google Scholar
• Gonda I. Systems and methods for effecting cessation of tobacco use. United States: Aradigm Corp; 2012.
   Google Scholar
• Wollmer P, Pieber TR, Gall M-A, et al. Delivering needle-free insulin using AERx iDMS (insulin diabetes management system) technology. Diabetes Technol Ther. 2007;9(Suppl 1):S57–64. doi: 10.1089/dia.2007.0206
   PubMedGoogle Scholar
• Brunner GA, Balent B, Ellmerer M, et al. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia. 2001;44(3):305–308. doi: 10.1007/s001250051618
   PubMed Web of Science ®Google Scholar
• Moses RG, Bartley P, Lunt H, et al. Safety and efficacy of inhaled insulin (AERx iDMS) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial. Diabet Med. 2009;26(3):260–267. doi: 10.1111/j.1464-5491.2008.02654.x
   PubMed Web of Science ®Google Scholar
• El Maalouf IR, Capoccia K, Priefer R. Non-invasive ways of administering insulin. Diabetes & metabolic syndrome. Diabetes Metab Syndr. 2022;16(4):102478. doi: 10.1016/j.dsx.2022.102478
   PubMedGoogle Scholar
• Al-Tabakha M, Arida A. Recent challenges in insulin delivery systems: a review. Indian J Pharm Sci. 2008;70(3):278–286. doi: 10.4103/0250-474X.42968
   PubMed Web of Science ®Google Scholar
• Gibbons A, Smyth HDC. Science and Technology of Nebulizers and Liquid-Based Aerosol Generators. In: Smyth HDC Hickey AJ, editors. Controlled Pulmonary Drug Delivery. (NY) New York: Springer New York; 2011. p. 223–236. doi: 10.1007/978-1-4419-9745-6_10.
   Google Scholar
• Kesser KC, Geller DE. New aerosol delivery devices for cystic fibrosis. Respir Care. 2009;54(6):754–767. doi: 10.4187/002013209790983250 discussion 767-8.
   PubMed Web of Science ®Google Scholar
• Wylie JL, House A, Mauser PJ, et al. Inhaled formulation and device selection: bridging the gap between preclinical species and first-in-human studies. Ther Deliv. 2018;9(5):387–404. doi: 10.4155/tde-2000-0000
   PubMed Web of Science ®Google Scholar
• Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs. 2003;63(22):2501–2520. doi: 10.2165/00003495-200363220-00015
   PubMed Web of Science ®Google Scholar
• Muellinger B, Bartholomew, J, de Kruij W. Aerosol Performance of the Pulmospray® Soft‐Mist Inhaler for Inhalation of High Amounts of Liquid Formulations. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 2021;34(5):A18–A19.
   Google Scholar
• Collins N. Nebulizer therapy in cystic fibrosis: an overview. J R Soc Med. 2009;102(Suppl 1):11–17. doi: 10.1258/jrsm.2009.s19003 Suppl 1.
   PubMed Web of Science ®Google Scholar
• Boe J, Dennis JH, O’Driscoll BR, et al. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J. 2001;18(1):228. doi: 10.1183/09031936.01.00220001
   PubMed Web of Science ®Google Scholar
• Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc. 2004;1(4):24–29.
   PubMedGoogle Scholar
• Komalla V, Haghi M, Kayser V. Biologics and vaccines for nasal and pulmonary drug delivery, in biologics and vaccines for nasal and pulmonary drug delivery. 2022.
   Google Scholar
• Ip AY, Arakawa T, Silvers H, et al. Stability of recombinant consensus interferon to air-jet and ultrasonic nebulization. J Pharm Sci. 1995;84(10):1210–1214. doi: 10.1002/jps.2600841013
   PubMed Web of Science ®Google Scholar
• Lamche H, Meade CM, Zierenberg B, et al. Process for nebulizing aqueous compositions containing highly concentrated insulin. In: 2011, Lamche Herbert Meade Christopher John Montagu Zierenberg Bernd Reimholz Ralph. United States Patent and Trademark Office: United States.
   Google Scholar
• Phyo P, Zhao X, Templeton AC, et al. Understanding molecular mechanisms of biologics drug delivery and stability from NMR spectroscopy. Adv Drug Delivery Rev. 2021;174:1–29. doi: 10.1016/j.addr.2021.02.007
   PubMed Web of Science ®Google Scholar
• Taube C, Bayer V, Zehendner CM, et al. Assessment of patient experiences with respimat(®) in everyday clinical practice. Pulm Ther. 2020;6(2):371–380. doi: 10.1007/s41030-020-00127-4
   PubMedGoogle Scholar
• Takaku Y, Kurashima K, Ohta C, et al. How many instructions are required to correct inhalation errors in patients with asthma and chronic obstructive pulmonary disease? Respir med. 2017;123:110–115. doi: 10.1016/j.rmed.2016.12.012
   PubMed Web of Science ®Google Scholar
• Usmani OS. Choosing the right inhaler for your asthma or COPD patient. Ther Clin Risk Manag. 2019;15:461–472. doi: 10.2147/TCRM.S160365
   PubMed Web of Science ®Google Scholar
• Matera MG, Ora J, Cazzola M. Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol. Ther Clin Risk Manag. 2015;11:1805–1811. doi: 10.2147/TCRM.S73581
   PubMed Web of Science ®Google Scholar
• Leclerc V, Lafferre M, Pavia D. Acute local tolerability of acidic aqueous vehicles delivered via respimat soft mist inhaler in hyperreactive asthma patients. Respiration. 2007;74(6):691–696. doi: 10.1159/000107739
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Longo P, Ziani OV, et al. Instant velocity and consistency of emitted cloud change by the different levels of canister filling with metered dose inhalers (MDIs), but not with Soft Mist Inhalers (SMIs): a bench study. Multidiscip Respir Med. 2017;12(1):13. doi: 10.1186/s40248-017-0096-1
   PubMedGoogle Scholar
• Lee HY, Song JH, Won H-K, et al. Comparing Inhaler use technique based on inhaler type in elderly patients with respiratory disease. Tuberc Respir Dis (Seoul). 2021;84(1):46–54. doi: 10.4046/trd.2020.0021
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Povero M. Acceptability and preference of three inhalation devices assessed by the handling questionnaire in asthma and COPD patients. Multidiscip Respir Med. 2015;11(1):7. doi: 10.1186/s40248-016-0044-5
   PubMedGoogle Scholar
• Kamin W, Frank M, Kattenbeck S, et al. A handling study to assess use of the respimat(®) soft mist™ inhaler in children under 5 years old. J Aerosol Med Pulm Drug Deliv. 2015;28(5):372–381. doi: 10.1089/jamp.2014.1159
   PubMed Web of Science ®Google Scholar
• Asakura Y, Nishimura N, Maezawa K, et al. Effect of switching tiotropium HandiHaler® to respimat® soft mist™ inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices. J Aerosol Med Pulm Drug Deliv. 2013;26(1):41–45. doi: 10.1089/jamp.2011.0941
   PubMed Web of Science ®Google Scholar
• Hamelmann E, Szefler SJ. Efficacy and safety of tiotropium in children and adolescents. Drugs. 2018;78(3):327–338. doi: 10.1007/s40265-018-0862-1
   PubMed Web of Science ®Google Scholar
• Zhang W, Xu L, Gao S, et al. Technical Evaluation of Soft Mist Inhaler Use in Patients with Chronic Obstructive Pulmonary Disease: a Cross-Sectional Study. Int J Chron Obstruct Pulmon Dis. 2020;15:1471–1479. doi: 10.2147/COPD.S253338.
   PubMed Web of Science ®Google Scholar
• Pernigotti D, Stonham C, Panigone S, et al. Reducing carbon footprint of inhalers: analysis of climate and clinical implications of different scenarios in five European countries. BMJ Open Respir Res. 2021;8(1):e001071. doi: 10.1136/bmjresp-2021-001071
   PubMed Web of Science ®Google Scholar
• Woodcock A, Beeh KM, Sagara H, et al. The environmental impact of inhaled therapy: making informed treatment choices. Eur Respir J. 2021;60(1):2102106. doi: 10.1183/13993003.02106-2021
   Web of Science ®Google Scholar
• Deshpande D, Blanchard J, Srinivasan S, et al. Aerosolization of lipoplexes using AERx pulmonary delivery system. AAPS PharmSci. 2002;4(3):E13. doi: 10.1208/ps040313
   PubMedGoogle Scholar
• Wilkinson M, Sugumar K, Milan SJ, et al.Mucolytics for bronchiectasis. Cochrane Database Syst Rev. 2018;(7). doi: 10.1002/14651858.CD001289.pub2
   PubMedGoogle Scholar
• Cipolla DC, Gonda I. Formulation technology to repurpose drugs for inhalation delivery. Drug discovery today: therapeutic strategies. Drug Discov Today Ther Strateg. 2011;8(3):123–130. doi: 10.1016/j.ddstr.2011.07.001
   Google Scholar
• Last TS, Winkler TE, Stemme G, et al. Self-sealing MEMS spray-nozzles to prevent bacterial contamination of portable inhalers for aqueous drug delivery. Biomed Microdevices. 2022;24(3):25. doi: 10.1007/s10544-022-00628-w
   PubMed Web of Science ®Google Scholar
• Kamin W, Krackhardt D, Gössl R, et al. A handling study to assess the use of the respimat® soft mist™ inhaler in children aged 4–12 years. Pulm Ther. 2015;1(1):53–63. doi: 10.1007/s41030-015-0002-y
   Google Scholar
• Oakes JM, Amirav I, Sznitman J. Pediatric inhalation therapy and the aerodynamic rationale for age-based aerosol sizes. Expert Opinion Drug Delivery. 2023;1–4. doi: 10.1080/17425247.2023.2209314.
   PubMed Web of Science ®Google Scholar
• Rossi V, Salimäki J, Sandler C, et al. Effectiveness of inhalation technique assessment service for patients with Respimat® inhaler. Pulm Pharmacol Ther. 2021;71:102077. doi: 10.1016/j.pupt.2021.102077
   PubMed Web of Science ®Google Scholar
• Brand P, Hederer B, Austen G, et al. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor techniquep. 1176–9106.
   Google Scholar
• Newman SP. Drug delivery to the lungs: challenges and opportunities. Ther Deliv. 2017;8(8):647–661. doi: 10.4155/tde-2017-0037.
   PubMed Web of Science ®Google Scholar
• Irvine DJ, Su X, Kwong B. Routes of delivery for biological drug products. Pharma Sci Encycl. 2013;1–48.
   Google Scholar
• Park JW, Lagniton PNP, Liu Y, et al. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci. 2021;17(6):1446–1460. doi: 10.7150/ijbs.59233
   PubMed Web of Science ®Google Scholar
• Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of sotrovimab on hospitalization or death among high-risk patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2022;327(13):1236–1246. doi: 10.1001/jama.2022.2832
   PubMed Web of Science ®Google Scholar
• Jeyanathan V, Afkhami S, D’Agostino MR, et al. Differential biodistribution of adenoviral-vectored vaccine following intranasal and endotracheal deliveries leads to different immune outcomes. Front Immunol. 2022;13:13. doi: 10.3389/fimmu.2022.860399
   Web of Science ®Google Scholar
• de Swart RL, de Vries RD, Rennick LJ, et al. Needle-free delivery of measles virus vaccine to the lower respiratory tract of non-human primates elicits optimal immunity and protection. NPJ Vaccines. 2017;2(1):22. doi: 10.1038/s41541-017-0022-8
   PubMedGoogle Scholar
• Ari A. PROMOTING SAFE and EFFECTIVE USE of AEROSOL DEVICES in COVID-19: rISKS and SUGGESTIONS for VIRAL TRANSMISSION. Expert Opin Drug Delivery. 2020;17(11):1509–1513. doi: 10.1080/17425247.2020.1811225
   PubMed Web of Science ®Google Scholar
• El-Sherbiny IM, El-Baz NM, Yacoub MH. Inhaled nano- and microparticles for drug delivery. Glob Cardiol Sci Pract. 2015;2015(1):2. doi: 10.5339/gcsp.2015.2
   PubMedGoogle Scholar
• Akhter S, Ahmad J, Rizwanullah M, et al. Nanotechnology-based inhalation treatments for lung cancer: state of the art. Nanotechnol Sci Appl. 2015;8:55–66. doi: 10.2147/NSA.S49052
   PubMedGoogle Scholar
• Zabczyk C, Blakey JD. The effect of connected “smart” inhalers on medication adherence. Front Med Technol. 2021;3. doi: 10.3389/fmedt.2021.657321
   PubMedGoogle Scholar
• Chan AHY, Pleasants AP, Dhand R, et al. Digital inhalers for asthma or chronic obstructive pulmonary disease: a scientific perspective. Pulm Ther. 2021;7(2):345–376. doi: 10.1007/s41030-021-00167-4
   PubMedGoogle Scholar